Werewolf Therapeutics reports Q3 EPS (36c), consensus (38c)

“Werewolf is delivering on the promise of its proprietary PREDATOR platform of conditionally activated immune therapeutics, marked by significant progress for our lead INDUKINE clinical programs, WTX-124 and WTX-330, and our first INDUCER T-cell engager candidate, WTX-1011,” said Daniel Hicklin, Ph.D., President and Chief Executive Officer of Werewolf. “For WTX-124, which received Fast Track Designation last month, we plan to provide an update later in the fourth quarter of 2025 on the path to a registration-enabling trial based on interim Phase 1/1b clinical trial data and feedback from an End of Phase 1 meeting with the FDA. At the same time, we plan to provide an update on the current Phase 1b/2 clinical trial of WTX-330 and a potential development plan for this program. Finally, we continue to make progress in IND-enabling studies for WTX-1011, our first INDUCER T cell Engager development candidate, and plan to nominate a differentiated target candidate by year-end.”